[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589991":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":43,"collaborators":20,"id":46,"slug":20,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":20,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":20,"enrollmentInfo":53,"targetDuration":20,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":20,"overallStatus":62,"whyStopped":20,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Atlantic Health System","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention - NaF PET","EXPERIMENTAL","Intervention\u002FExperimental Arm - non-cardiogenic thromboembolic stroke patients to undergo NaF PET-CT",[13],"Drug: NaF PET-CT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","NaF PET-CT","Following a non-cardiogenic thromboembolic stroke, patients will undergo NaF PET-CT imaging to identify the culprit plaque and any other vulnerable plaques at high risk for rupture",[9],null,[22],{"facility":23,"status":20,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Overlook Medical Center","Summit","New Jersey","07901","United States","US",{"type":30,"coordinates":31},"Point",[32,33],-74.36468,40.71562,{"lat":33,"lon":32},[36,41],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"James Cassuto, MD, PhD","CONTACT","908-522-2337","james.cassuto@atlantichealth.org",{"name":37,"role":42,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"type":42,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"jcassuto","MD","100589991",false,"NCT06961604","A Novel Method for Determination of Thromboembolic Stroke Origin","Inclusion Criteria: 18 years of age or older with a non-cardiogenic thromboembolic stroke in the past 14 days.\n\nExclusion Criteria: Less than 18 years of age, any other kind of stroke, not clinically stable to undergo PET-CT","ALL","18 Years",{"count":54,"type":55},20,"ESTIMATED","INTERVENTIONAL",[58],"EARLY_PHASE1","Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. Prior studies have shown a high degree of correlation between NaF PET+ lesions and high-risk plaque features on high resolution MRI, including mirocalcification, necrosis, and ulceration.",[61],"Thromboembolic Stroke","NOT_YET_RECRUITING","2025-05-06",{"date":65,"type":66},"2025-05-08","ACTUAL",{"date":68,"type":55},"2025-06-01",{"date":70,"type":55},"2026-05-31",{"name":5,"class":6},1]